Genzyme Corporation and Medicines for Malaria Venture (MMV) Announce New Collaboration with Advinus Therapeutics (P) Ltd. to Accelerate Discovery of Novel Therapies for Malaria

CAMBRIDGE, Mass. and GENEVA--(BUSINESS WIRE)--Genzyme Corp. (Nasdaq: GENZ), a global leader in biotechnology, and Medicines for Malaria Venture (MMV), a not-for-profit virtual research and development (R&D) organization dedicated to reducing the burden of malaria, announced today a new collaboration with India’s Advinus Therapeutics Ltd. The collaboration seeks to develop new, improved treatments for specific patient groups most at risk for malaria, an often fatal infectious disease of developing countries, particularly affecting pregnant women and infants.

MORE ON THIS TOPIC